AMGN vs. BMRN: Amgen vs. BioMarin Pharmaceutical Stock Comparison
How do Amgen (AMGN) and BioMarin Pharmaceutical (BMRN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Amgen (AMGN) and BioMarin Pharmaceutical (BMRN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | AMGN | BMRN |
|---|---|---|
| Name | Amgen Inc. Common Stock | BioMarin Pharmaceutical Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 249.05 billion USD | 10.85 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 17, 1983 | July 26, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AMGN | BMRN |
|---|---|---|
| Total Return (1Y) | 48.82% | 8.82% |
| Total Return (3Y, Annualized) | 24.31% | -12.54% |
| Total Return (5Y, Annualized) | 20.67% | -7.51% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AMGN | BMRN |
|---|---|---|
| Volatility (1Y, Annualized) | 29.12% | 35.50% |
| Beta (5Y) | 0.43 | 0.24 |
| Max Drawdown (5Y) | -24.86% | -57.64% |
| Avg. Volume (3M) | 2.76M | 2.28M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AMGN | BMRN |
|---|---|---|
| Sharpe Ratio (1Y) | 1.53 | 0.13 |
| Sortino Ratio (1Y) | 2.36 | 0.23 |
Profitability
ROE (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Amgen (AMGN) reports 78.35%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
78.35%
- Max
- 109.18%
- AMGN
- 78.35%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Amgen (AMGN) reports 24.14%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.14%
- AMGN
- 24.14%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Amgen (AMGN) at 35.79% and BioMarin Pharmaceutical (BMRN) at 26.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.79%
- Max
- 83.12%
- AMGN
- 35.79%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AMGN | BMRN |
|---|---|---|
| ROE (TTM) | 78.35% | -0.31% |
| ROA (TTM) | 8.91% | 3.89% |
| Net Margin (TTM) | 24.14% | -0.52% |
| Operating Margin (TTM) | 35.79% | 26.58% |
| Gross Margin (TTM) | 72.47% | 53.21% |
Growth
Revenue Growth
Both Amgen (AMGN) at 9.95% and BioMarin Pharmaceutical (BMRN) at 12.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while BioMarin Pharmaceutical (BMRN) at -18.55% is closer to the peer norm — faster per-share earnings growth for AMGN.
Growth Metrics
| Metric | AMGN | BMRN |
|---|---|---|
| Revenue Growth (YoY) | 9.95% | 12.87% |
| Revenue Growth (3Y CAGR) | 11.77% | 15.40% |
| EPS Growth (YoY) | 88.23% | -18.55% |
| EPS Growth (3Y CAGR) | 5.52% | 33.89% |
Financial Strength
Current Ratio (MRQ)
Both Amgen (AMGN) at 1.48 and BioMarin Pharmaceutical (BMRN) at 2.44 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AMGN
- 1.48
- Min
- 0.10
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: BioMarin Pharmaceutical (BMRN) at 0.67 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.76
- AMGN
- 3.76
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AMGN | BMRN |
|---|---|---|
| Current Ratio (MRQ) | 1.48 | 2.44 |
| Debt / Equity (MRQ) | 3.76 | 0.67 |
| Net Debt / EBITDA | 2.31 | 4.04 |
Dividends
Dividend Yield (TTM)
BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.16%
- AMGN
- 2.16%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
57.62%
- AMGN
- 57.62%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AMGN | BMRN |
|---|---|---|
| Dividend Yield (TTM) | 2.16% | 0.00% |
| Dividend Payout Ratio (TTM) | 57.62% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Amgen (AMGN) trades at 26.69 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.69
- Max
- 85.34
- Q3
- 43.46
- AMGN
- 26.69
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Amgen (AMGN) at 6.40 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.40
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AMGN
- 6.40
- Q1
- 3.01
- Min
- 0.01
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
P/B Ratio (MRQ)
BioMarin Pharmaceutical (BMRN) at 1.73 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.35
- AMGN
- 17.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AMGN | BMRN |
|---|---|---|
| P/E Ratio (TTM) | 26.69 | -- |
| P/S Ratio (TTM) | 6.40 | 2.97 |
| P/B Ratio (MRQ) | 17.35 | 1.73 |
| Free Cash Flow Yield (TTM) | 2.96% | -0.15% |